Deal covers Roche’s access to CNS subset.

Roche subscribed to LifeSpan Biosciences’ DrugTarget Database™. Under the terms of the multiyear agreement, Roche will gain access to the entire CNS subset of the DrugTarget Database.

The CNS part includes informatics on more than 3,400 genes, 886 immunohistochemistry (IHC) reports with localization information on more than 450 potential drug targets selected by pharmaceutical company subscribers, as well as search and analysis tools.

“Roche’s commitment to the DrugTarget Database consortium supports LifeSpan’s vision of achieving a comprehensive human tissue localization resource for all therapeutically important proteins,” comments Joseph P. Brown, Ph.D., LifeSpan’s CEO. “With current subscribers, LifeSpan expects to add over new 200 targets to the database.”

In addition to accessing previously generated data, subscribers to the DrugTarget Database nominate new targets that they consider to be of therapeutic relevance, regardless of gene family. For each protein studied, LifeSpan will provide IHC localization information on 75 human normal and diseased tissues at the cellular level, often using custom generated antibodies.

Previous articleGulf Coast Consortium Uses Invitrogen’s Stealth siRNA Libraries
Next articleCompugen and Teva to Discover Biomarkers for Drug Toxicity